FRANKFURT, Germany (AFP) — BioNTech said Thursday that it expected its Covid-19 vaccine, jointly developed with Pfizer, to be available to 12 to 15-year-olds in Europe from June. The German firm’s CEO Ugur Sahin told Der Spiegel weekly that it was “in the final stretches” of preparing its submission for European regulatory approval. The evaluation of the trial data “takes four to six weeks on average”, he added. Vaccinating children is seen as a crucial […]
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.